API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 4 sources · 6 days · First seen · Last updated

Chilean biosimilar pharmaceutical regulation

Overview

The Chilean Ministry of Health has proposed a decree to modify the Regulation of the National Control System for Pharmaceutical Products for Human Use. The proposal seeks to incorporate biosimilars into the regulatory framework for demonstrating bioequivalence and interchangeability. If enacted, this would allow pharmacies to exchange prescribed biological medicines for certified biosimilars.

In parallel, medical experts at the “Biosimilares en Cáncer” congress argued that biosimilar medicines are not sufficiently integrated into national health policies. Specialists noted that despite potential healthcare savings, these treatments lack a significant presence in national health baskets, particularly in oncology. Francisco Vidangossy, president of the Fundación Cáncer Vida, indicated that the limited use of biosimilars in oncology coverage is difficult to justify under current budgetary constraints and intends to address this in 2027 health budget discussions.

Entities

Ministry of Health · Federación de Asociaciones Científico-Médicas Españolas · Farmaindustria · European Medicines Agency · ISPOR Chile

Timeline

  1. [HEALTH] 2 sources
    Medical experts advocate for biosimilars and prescription autonomy

    Experts in Chile call for increased use of biosimilars to reduce healthcare costs, while Spanish medical professionals advocate for greater prescription autonomy amid pending pharmaceutical law reforms.

  2. [HEALTH] 2 sources
    Chile proposes regulatory changes for biosimilar drug interchangeability

    Chile's Ministry of Health is seeking to modify regulations to allow the pharmacy-level interchangeability of biosimilar drugs.

Sources

comcantabria.es · estadodiario.com · g5noticias.cl · mitdf.com.ar